---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-291448"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2025-11-21T23:59:59+00:00"
generated_at: "2026-05-16T17:40:40.278779+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cullinan Therapeutics terminates exclusive MIT license for CLN-617; program abandoned

## Summary
- Terminates Exclusive Patent License Agreement with MIT for CLN-617, effective Feb 18, 2026.
- Decision based on not pursuing further development of CLN-617 cancer immunotherapy.
- Company will return licensed patent rights for CLN-617 technology to MIT.
- CLN-617 was an exclusive worldwide license for a cancer immunotherapy product.

## SEC filing metadata
- accession: 0001193125-25-291448
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2025-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312525291448/0001193125-25-291448-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312525291448/cgem-20251118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-291448
- JSON: https://secwatch.observer/filing/0001193125-25-291448.json
- Plain text: https://secwatch.observer/filing/0001193125-25-291448.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.